Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV001045325 | SCV001209166 | uncertain significance | Hereditary cancer-predisposing syndrome | 2020-06-03 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with RAD50-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces methionine with isoleucine at codon 100 of the RAD50 protein (p.Met100Ile). The methionine residue is highly conserved and there is a small physicochemical difference between methionine and isoleucine. |
| Ambry Genetics | RCV001045325 | SCV004065005 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-06-24 | criteria provided, single submitter | clinical testing | The p.M100I variant (also known as c.300G>C), located in coding exon 3 of the RAD50 gene, results from a G to C substitution at nucleotide position 300. The methionine at codon 100 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |